Redeye comments on TH1NG’s Q2 report, which was below our expectations in terms of revenues but also...
Redeye lowers its valuation of Fuud after a somewhat Q2 2022 report on both the top and bottom lines...
Projektportföljen fortsätter växa för vindkraftbolaget och utöver det har Heixon vunnit en viktig ak...
Redeye comments on InDex Pharmaceuticals following its Q2 2022 report.
Fellow Bank’s H1 figures were weak due to ECL changes driven by the loan book growth and non-recurri...
Redeye leaves a comment on the Q2 report published by Initiator Pharma earlier this morning.
Redeye comments on Safello's Q2'22 report, which was impacted by a weaker crypto market.
Redeye maintains its fair value range unchanged after reviewing Netmore’s Q2 report, which was somew...
Redeye concludes that Q2 was in line with sales estimates but included a higher cost base than expec...
Redeye leaves its comments on Acarix following the announcement of its Q2 report.
Redeye comments on yesterday’s Q2 report from Vicore, which came in as expected.
Saniona: Our Q2 Comment
Vow reported strong headline figures across the board for H1.
Redeye comments on LIDDS Q2’22 report. The company advances its projects, in particular with regard ...
Utvecklingsbolaget Tendo redovisade som förväntat ingen omsättning under det andra kvartalet.
Forecasts for 2023-24e lowered by ~1% Record order book, partnerships have lowered risk Fair value a...
Q2 sales +6% above ABGSCe We make positive revisions on the back of the report Good start to Q3, mon...
The Phase IIb trial of mesdopetam (partnered with Ipsen) in levodopa-induced dyskinesias in Parkinso...
Redeye comments on aXichem’s Q2’22 report. We are encouraged to see sales for H1 2022 reaching SEK 1...
Redeye comments on Fluoguide’s Q2 2022 report, and we judge that the company is laser-focused on del...
